Clinical Trials

I-AbbVie/Elagolix in combination with Estradiol/Norethindrone Acetate

  • Primary Investigator: David Archer, MD
  • Start date: 4/6/2016

I-LBR/Myovant-Relugoliz co-administered with and without low-dose Estradiol and Norethindrone Acetate in women with heavy menstrual bleeding associated with uterine fibroids

  • Primary Investigator: David Archer, MD
  • Start date: 4/6/2017

I-Chiltern/OBE2109 alone and in combination with add-back therapy

  • Primary Investigator: David Archer, MD
  • Start date: 9/30/2017

I-AbbVie-Elagolix in premenopausal women with heavy menstrual bleeding associated with uterine fibroids

  • Primary Investigator: David Archer, MD
  • Start date: 5/3/2017

I-Genentech/PPD/Omalizumab in subjects with chronic rhinosinusitis with nasal polyps

  • Primary Investigator: Joseph Han, MD, FARS, FAAOA
  • Summary: Open to enrollment for patients with moderate to severe nasal polyp disease and have failed other treatments, including sinus surgery.  Study drug and clinic follow up visits are provided at no cost.
  • Point of contact: Laura Stone, RN, BSN, CCRC | 757.388.6240
  • Start date: 10/8/2017

I-Arrinex/Clarifix cryotherapy device in patients with chronic rhinitis (FROS)

  • Primary Investigator: Joseph Han, MD, FARS, FAAOA
  • Summary: FDA approved treatment  option for patients with chronic rhinitis (running nose or post-nasal drip). This is a registry of patients who will receive treatment and follow up visits at no cost.
  • Point of contact: Laura Stone, RN, BSN, CCRC | 757.388.6240
  • Start date: 10/30/2017

I-Sinopsys/Lacrimal Stent for transcaruncular ethmoid sinus access

  • Primary Investigator: Joseph Han, MD, FARS, FAAOA
  • Summary: Open to people with chronic sinus infections diagnosed by an ENT doctor that have lasted for more than 12 weeks and have not responded to standard treatment.  Exclusions include previous sinus surgery or facial trauma. Treatment and follow up visits are provided at no cost.
  • Point of contact: Laura Stone, RN, BSN, CCRC | 757.388.6240
  • Start date: 1/13/2017

Novo Nordisk/Liraglutide on sudomotor function and inflammation in Type 2 diabetes

  • Primary Investigator: Aaron Vinik, MD, PhD, FCP, MACP, FACE
  • Summary: The purpose of this study is to examine the effects of GLP-1 receptor agonist Liraglutide on autonomic sudomotor function and endothelial and neurovascular functions, as well as markers of inflammation in patients with type 2 diabetes mellitus. The primary objective will be changes in peripheral autonomic function using sudorimetry (Sudoscan) after one year of treatment.
  • Point of contact: Carolina Casellini, MD and Henri Parson, PhD
  • Start date: 8/1/2015

Veroscience/timed Bromocriptine-QR therapy

  • Primary Investigator: Aaron Vinik, MD, PhD, FCP, MACP, FACE
  • Summary: The main objective of this study is to demonstrate the effects of early dopaminergic activation on the autonomic nervous system in subjects with newly diagnosed vs. established type 2 diabetes. The primary endpoint is the effect of Bromocriptine QR on changes in autonomic function measured by assessing sympathetic and parasympathetic function using conventional measures of autonomic function, including power spectral analysis of heart rate as well as peripheral autonomic function using sudorimetry and laser scanning of peripheral microvascular autonomic control
  • Point of contact: Carolina Casellini, MD and Henri Parson, PhD
  • Start date: 6/1/2015

I-Viromed/Phase III study to assess VM202

  • Primary Investigator: Aaron Vinik, MD, PhD, FCP, MACP, FACE
  • Summary: This is a Phase III, Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of VM202, a new compound for the treatment of Painful Diabetic Peripheral Neuropathy in subjects with Type 1 or Type 2 Diabetes.
  • Point of contact: Carolina Casellini, MD and Henri Parson, PhD
  • Start date: 5/16/2016

I-NYX-2925 in subjects with neuropathic pain associated with diabetic peripheral neuropathy

  • Primary Investigator: Aaron Vinik, MD, PhD, FCP, MACP, FACE
  • Summary: The main objective of this study is to evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the neuropathic pain associated with diabetic peripheral neuropathy. The secondary endpoints will assess the effects of multiple dose levels of NYX-2925 versus placebo on pain characteristics, sleep interference, health status, psychological state, and global improvement and to assess the safety and tolerability of multiple dose levels of NYX-2925
  • Point of contact: Carolina Casellini, MD and Henri Parson, PhD
  • Start date: 9/22/2017

Additional clinical trials

CONRAD

CONRAD's main objective is to help develop safe, acceptable, affordable products and methods that provide contraception and/or prevent the sexual transmission of HIV/AIDS and other infections. Find more information about CONRAD’s clinical trials:

Jones Institute for Reproductive Medicine

The Jones Institute continues its tradition of cutting-edge basic science and clinically applied research. To learn more about Jones Institute clinical trials, please contact us at 757.446.7100.

Obstetrics and Gynecology Clinical Research Center

The OBGYN Clinical Research Center conducts clinical trials in various areas, including:

Otolaryngology Head and Neck Surgery

Otolaryngology Head and Neck Surgery collaborates with local institutions, government agencies and biomedical companies to perform clinical research trials. Learn more about active studies that are open to enrollment.

Pediatrics

Pediatrics hosts modern research laboratories and comfortable, child-friendly clinical facilities for children enrolled in research studies. To learn more about ongoing current trials, please contact the Clinical Research Unit by phone at 757.668.6416.

Psychiatry and Behavioral Sciences

Psychiatry and Behavioral Sciences faculty are engaged in ongoing research in the areas of sleep disorders, personality assessment, neuropsychology, psychopharmacology, cognitive therapy, and specific areas of psychopathology that may particularly include depression, eating disorders, ADHD and more. Learn more about active studies that are open to enrollment.

Strelitz Diabetes Center

Through the integration of basic science and clinical research, the Strelitz Diabetes Center conducts numerous clinical trials designed to develop possible new treatments for diabetes and diabetic complications. Find more information about active clinical trials here, contact the Diabetes Research Hotline at 757.446.7933 or email us at diabetesresearch@evms.edu.